On Friday, 2Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $4.93 which represents a slight increase of $0.17 or 3.57% from the prior close of $4.76. The stock opened at $4.83 and ...

Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...

欢迎关注凯莱英药闻近期，诺和诺德在基因编辑领域进一步加码；首先是在2024年6月，公司以最高4000万美元收购2seventy bio的A ...

Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

On Wednesday, 2Seventy Bio Inc (TSVT) stock saw a decline, ending the day at $4.32 which represents a decrease of $-0.45 or -9.43% from the prior close of $4.77. The stock opened at $4.32 and touched ...

TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...

Leerink Partners调整了对2Seventy Bio Inc. (NASDAQ: TSVT)的展望，将该股票的目标价从之前的15.00美元上调至25.00美元，同时维持"优于大市"评级。 此次调整是在KarMMa-9试验终止后做出的，该试验原本预计将成为自体BCMA CAR-T疗法Abecma收入增长的重要贡献者。 根据Leerink Partners的分析，尽管KarMMa-9试验终 ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...

Will peptide-drug conjugates become the "next big thing" in targeted cancer therapy? (Endpoints News) Bristol Myers Squibb ...

Wegovy is approved for obesity but is also under investigation in a range of other indications. Image credit: Shutterstock / KK Stock. Novo Nordisk’s Wegovy has shown promising benefits in treating a ...